Drug Monograph
Denosumab
Prolia (60 mg) · Xgeva (120 mg)
Pharmacokinetic Profile
Half-Life
25–28 days
Metabolism
Reticuloendothelial system (proteolysis)
Protein Binding
N/A (monoclonal antibody)
Bioavailability
61–62% (SC)
Volume of Distribution
~5.2 L (central)
Clinical Information
Drug Class
RANKL Inhibitor
Available Doses
60 mg/mL PFS; 120 mg/1.7 mL vial
Route
Subcutaneous only
Renal Adjustment
None required; monitor Ca2+ if CrCl <30
Hepatic Adjustment
Not studied
Pregnancy
Contraindicated (Prolia); Fetal harm expected (Xgeva)
Lactation
Unknown excretion; not recommended
Schedule / Legal Status
Rx only (not a controlled substance)
Black Box Warning
Yes — Severe hypocalcemia in advanced CKD
Generic / Biosimilar Available
Yes — multiple biosimilars (2024–2025)
Indications for Denosumab
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Postmenopausal osteoporosis at high fracture risk | Postmenopausal women | Monotherapy | FDA Approved (Prolia) |
| Male osteoporosis at high fracture risk | Adult men | Monotherapy | FDA Approved (Prolia) |
| Glucocorticoid-induced osteoporosis | Adults on ≥7.5 mg/day prednisone equivalent for ≥6 months | Monotherapy | FDA Approved (Prolia) |
| Bone loss — androgen deprivation therapy | Men with nonmetastatic prostate cancer on ADT | Monotherapy | FDA Approved (Prolia) |
| Bone loss — aromatase inhibitor therapy | Women with breast cancer on adjuvant AI therapy | Monotherapy | FDA Approved (Prolia) |
| Prevention of skeletal-related events — bone metastases | Adults with solid tumors metastatic to bone | Adjunctive to anticancer therapy | FDA Approved (Xgeva) |
| Prevention of skeletal-related events — multiple myeloma | Adults with multiple myeloma | Adjunctive | FDA Approved (Xgeva) |
| Giant cell tumor of bone (GCTB) | Adults and skeletally mature adolescents; unresectable or resection causes severe morbidity | Monotherapy | FDA Approved (Xgeva) |
| Hypercalcemia of malignancy | Adults refractory to IV bisphosphonate therapy | Monotherapy | FDA Approved (Xgeva) |
Denosumab is the first-in-class RANKL inhibitor approved by the FDA (2010). It is marketed as two distinct products: Prolia (60 mg every 6 months for osteoporosis-related indications) and Xgeva (120 mg every 4 weeks for oncology indications). Patients must not receive both products concurrently. The AACE/ACE 2020 guidelines position denosumab as initial therapy for postmenopausal women with very low T-scores, multiple fractures, or intolerance to bisphosphonates.
Off-Label Uses
Adjuvant breast cancer bone protection (early-stage): Some guidelines support denosumab to reduce fracture risk in postmenopausal women on aromatase inhibitors beyond the FDA-approved bone-loss indication; evidence for disease-free survival benefit remains mixed. Evidence quality: Moderate.
Aneurysmal bone cyst (ABC): Case series report radiological response when surgical resection is not feasible, but controlled trial data are lacking. Evidence quality: Low.
Dosing
Osteoporosis & Treatment-Induced Bone Loss (Prolia)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Postmenopausal osteoporosis — high fracture risk | 60 mg SC Q6M | 60 mg SC Q6M | 60 mg Q6M | Supplement with Ca 1000 mg + vit D ≥400 IU daily Administer in upper arm, thigh, or abdomen |
| Male osteoporosis — high fracture risk | 60 mg SC Q6M | 60 mg SC Q6M | 60 mg Q6M | Same dosing as postmenopausal women (FDA PI) |
| Glucocorticoid-induced osteoporosis | 60 mg SC Q6M | 60 mg SC Q6M | 60 mg Q6M | For patients on ≥7.5 mg/day prednisone equivalent, expected ≥6 months ACR 2022 guidelines: consider after bisphosphonate failure or in high-risk patients |
| ADT-associated bone loss — prostate cancer | 60 mg SC Q6M | 60 mg SC Q6M | 60 mg Q6M | For nonmetastatic prostate cancer; do NOT use Xgeva concurrently |
| AI-associated bone loss — breast cancer | 60 mg SC Q6M | 60 mg SC Q6M | 60 mg Q6M | For women at high fracture risk on adjuvant aromatase inhibitors |
Oncology Indications (Xgeva)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Skeletal-related event prevention — bone metastases or multiple myeloma | 120 mg SC Q4W | 120 mg SC Q4W | 120 mg Q4W | Supplement Ca and vit D to prevent hypocalcemia Steady state reached by ~6 months |
| Giant cell tumor of bone (GCTB) | 120 mg SC on Days 1, 8, 15 | 120 mg SC Q4W | 120 mg Q4W | Loading phase (3 doses in first month), then monthly For skeletally mature adolescents: confirm closed epiphyseal plates + weight ≥45 kg |
| Hypercalcemia of malignancy — bisphosphonate-refractory | 120 mg SC on Days 1, 8, 15 | 120 mg SC Q4W | 120 mg Q4W | Same loading schedule as GCTB; median time to response ~9 days |
Renal and Hepatic Considerations
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment (any degree, including dialysis) | No dose adjustment | Standard dose | Standard | PK unaffected by renal function. However, patients with eGFR <30 are at markedly elevated risk of severe hypocalcemia Evaluate for CKD-MBD before initiating; monitor Ca weekly x4 wks, then monthly |
| Hepatic impairment | No data | Standard dose assumed | Standard | No clinical studies conducted; monoclonal antibodies are not hepatically metabolized |
Clinical Pearl: Discontinuation Planning
Denosumab must not be stopped abruptly. Bone turnover markers rebound above baseline ~9 months after the last dose, and BMD returns to pretreatment levels within 18 months. Multiple vertebral fractures have been reported as early as 7 months post-discontinuation. If stopping denosumab, transition to a bisphosphonate (typically zoledronic acid 5 mg IV as a single bridging dose 6 months after the last denosumab injection) to preserve BMD gains (FDA PI, AACE 2020).
Pharmacology
Mechanism of Action
Denosumab is a fully human IgG2 monoclonal antibody that binds with very high affinity (Kd ~3 × 10-12 mol/L) to RANKL, a cytokine essential for the formation, activation, and survival of osteoclasts. By sequestering RANKL, denosumab prevents its interaction with RANK on the osteoclast surface, effectively halting osteoclast-mediated bone resorption. This mechanism differs fundamentally from bisphosphonates, which act on mature osteoclasts already adherent to bone surfaces. In clinical studies, a single 60 mg dose reduced the bone resorption marker serum CTX by approximately 85% within 3 days, with maximal suppression sustained through the 6-month dosing interval. The effect is fully reversible upon discontinuation, which is both a clinical advantage (predictable offset) and a risk (rebound bone loss and vertebral fractures if not transitioned to alternative therapy).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability 61–62% (SC); Tmax 10 days (range 3–21 days); Cmax 6.75 mcg/mL after 60 mg | Slow absorption allows convenient Q6M dosing for osteoporosis; food does not affect absorption |
| Distribution | Vd ~5.2 L (central); seminal fluid concentration ~2% of serum levels | Limited distribution outside vascular and interstitial compartments, consistent with IgG antibody behavior; no contraception needed for male partners |
| Metabolism | Catabolized by the reticuloendothelial system (proteolysis to peptides and amino acids); no CYP involvement | No hepatic CYP metabolism eliminates conventional drug-drug interaction risk at the metabolic level |
| Elimination | t½ 25.4 days (Prolia, 60 mg Q6M) to 28 days (Xgeva, 120 mg Q4W); nonlinear PK at doses <60 mg, approximately dose-proportional above; minimal renal filtration | Long half-life supports infrequent dosing; no dose adjustment for renal impairment, but hypocalcemia risk increases markedly at eGFR <30 |
Side Effects
Safety data below are primarily from the FREEDOM trial (N = 7808, postmenopausal osteoporosis) for Prolia, and from the integrated SRE prevention trials (N = 5723) for Xgeva, unless otherwise noted.
≥10%
Very Common (Prolia — FREEDOM Trial)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Back pain | 34.7% vs 34.6% placebo | Most common reported event; marginal difference from placebo suggests this is largely attributable to the underlying disease |
| Pain in extremity | 11.7% vs 11.1% placebo | Mild excess over placebo; typically does not require dose modification |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Musculoskeletal pain | 7.6% vs 7.5% placebo | May overlap with underlying osteoporosis-related pain |
| Hypercholesterolemia | 7.2% vs 6.1% placebo | Monitor lipid panel; clinical significance uncertain |
| Cystitis | 5.9% vs 5.8% placebo | Marginal increase; treat as per standard UTI guidelines |
| Upper respiratory tract infection | 4.9% vs 4.3% placebo | RANKL expressed on lymphoid cells; monitor for infections |
| Peripheral edema | 4.9% vs 4.0% placebo | Evaluate cardiovascular causes if significant |
| Sciatica | 4.6% vs 3.8% placebo | Manage symptomatically; not a dose-limiting effect |
| Eczema / Dermatitis | 3.0% vs 1.7% placebo | Statistically significant increase (P < 0.001 in FREEDOM); consider discontinuation if severe |
| Flatulence | 2.2% vs 1.4% placebo | Generally mild and self-limiting |
| Rash | 2.5% vs 2.0% placebo | Usually non-specific; distinguish from hypersensitivity reactions |
| Hypocalcemia (serum Ca <8.5 mg/dL) | 1.7% vs 0.4% placebo | More common with renal impairment; correct Ca and vit D before dosing |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypocalcemia (CKD patients) | 29% (CrCl <30, unsupplemented) | Within 2–4 weeks of dosing | The 29% rate (Ca <7.5 mg/dL or symptomatic) is from an FDA PK study where patients did NOT receive calcium/vitamin D; risk is lower with supplementation but remains substantial. IV calcium may be needed; monitor weekly x4 weeks then monthly in CKD; supplement with activated vitamin D; fatal cases reported |
| Osteonecrosis of the jaw (ONJ) | <0.1% (Prolia, extension data); 2.2% (Xgeva, oncology) | Months to years; risk increases with duration | Dental examination before initiating; avoid invasive dental procedures during treatment; refer to oral surgeon if suspected ONJ |
| Atypical femoral fracture | Very rare | Usually after prolonged use (>3–5 years) | Evaluate any thigh or groin pain with imaging; consider discontinuation if confirmed; assess contralateral femur |
| Multiple vertebral fractures (post-discontinuation) | ~5–7% (within 18 months of stopping) | As early as 7 months (average 19 months) after last dose | Never abruptly discontinue; transition to bisphosphonate (e.g., zoledronic acid IV) 6 months after last dose |
| Serious infections (cellulitis, endocarditis) | 4.0% vs 3.3% placebo (hospitalized infections) | Any time during treatment | Prompt medical evaluation for signs of infection; consider risk-benefit in immunosuppressed patients; cellulitis 0.4% vs <0.1% placebo |
| Anaphylaxis / Severe hypersensitivity | Rare (postmarketing) | Minutes to hours post-injection | Emergency management; permanent discontinuation |
DC
Discontinuation Rates
Postmenopausal Osteoporosis (Prolia, FREEDOM 3-yr)
2.4% vs 2.1% placebo
Top reasons: Back pain, constipation
10-Year Extension (Prolia, open-label)
7.7% (cumulative over 7-yr extension)
Top reasons: Adverse events (not further specified in extension data)
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Back pain | Most frequent reason | Marginally higher than placebo; difficult to separate from disease |
| Constipation | Listed among top reasons | Calcium and vitamin D supplementation may contribute |
| ONJ (Xgeva oncology) | Most common reason for Xgeva discontinuation | Risk increases with cumulative exposure; median onset after 13 doses |
Managing Hypocalcemia — The Critical Safety Concern
Hypocalcemia is the most clinically significant adverse effect of denosumab and is the focus of the FDA boxed warning. Risk is substantially amplified in patients with advanced CKD (eGFR <30), CKD-MBD, hypoparathyroidism, or concurrent calcimimetic use. Before every dose: ensure calcium is repleted, 25(OH)D is above 20 ng/mL, and in CKD patients check iPTH and 1,25(OH)2D. In advanced CKD, monitor serum calcium weekly for the first month, then monthly. Activated vitamin D (calcitriol or alfacalcidol) may be needed instead of cholecalciferol.
Drug Interactions
No formal drug-drug interaction studies have been conducted with denosumab. As a monoclonal antibody, it is not metabolized by CYP enzymes and is unlikely to interact through conventional pharmacokinetic pathways. Interactions are primarily pharmacodynamic, centered on calcium homeostasis and additive bone-resorption effects.
Major
Calcimimetics (cinacalcet, etelcalcetide)
MechanismAdditive calcium-lowering effect; calcimimetics suppress PTH, reducing calcium release from bone
EffectSevere, potentially life-threatening hypocalcemia
ManagementMonitor calcium closely; ensure adequate supplementation; consider alternative to calcimimetic or use with extreme caution under specialist supervision
FDA PI
Major
Xgeva (denosumab 120 mg)
MechanismSame active ingredient; additive RANKL inhibition resulting in excessive bone turnover suppression
EffectIncreased risk of hypocalcemia, ONJ, atypical fracture; no additional efficacy benefit
ManagementNever use Prolia and Xgeva concurrently; choose one product based on indication
FDA PI
Moderate
Systemic corticosteroids
MechanismCorticosteroids reduce intestinal calcium absorption and increase renal calcium excretion
EffectAdditive hypocalcemia risk; corticosteroids also independently accelerate bone loss
ManagementEnsure adequate calcium and vitamin D supplementation; monitor serum calcium; denosumab is FDA-approved for GIO at ≥7.5 mg prednisone
FDA PI
Moderate
Immunosuppressants (e.g., tacrolimus, mycophenolate, rituximab)
MechanismAdditive immunosuppressive effects; RANKL is expressed on lymphoid cells and plays roles in immune function
EffectPotentially increased risk of serious infections
ManagementAssess individual risk-benefit before initiating; monitor for signs of infection; consider alternative antiresorptive in heavily immunosuppressed patients
FDA PI
Moderate
Other calcium-lowering drugs (bisphosphonates, loop diuretics)
MechanismAdditive reduction in serum calcium through different pathways
EffectEnhanced hypocalcemia risk
ManagementAvoid concurrent bisphosphonate + denosumab for the same indication; if using loop diuretics, monitor serum calcium more frequently
Lexicomp
Minor
Angiogenesis inhibitors (bevacizumab, sunitinib)
MechanismBoth independently increase risk of ONJ through impaired bone and mucosal healing
EffectPotentially additive risk of osteonecrosis of the jaw
ManagementDental evaluation before starting; good oral hygiene; report jaw symptoms promptly
LexicompMonitoring
-
Serum Calcium
Baseline; 10–14 days post-dose (first dose); then per clinical need
Routine In advanced CKD (eGFR <30): weekly for first 4 weeks after each dose, then monthly. Correct hypocalcemia before each injection. Monitor also phosphorus and magnesium in predisposed patients. -
25(OH) Vitamin D
Baseline; then annually
Routine Ensure levels ≥20 ng/mL before initiating therapy. Supplement with at least 400 IU vitamin D daily. In CKD patients, also check 1,25(OH)2D and iPTH. -
Pregnancy Test
Before each dose
Routine Required in all females of reproductive potential prior to every administration of Prolia. Denosumab is contraindicated in pregnancy (Prolia) and expected to cause fetal harm (Xgeva). -
Bone Mineral Density
Baseline; then every 1–2 years
Routine DXA scan at lumbar spine and hip. In FREEDOM trial, continuous BMD gains were observed over 10 years. Monitor to assess treatment response and inform continuation or transition decisions. -
Oral Health Assessment
Baseline; then at least annually
Routine Dental examination with preventive dentistry before starting treatment. Advise patients on good oral hygiene. ONJ risk increases with duration of exposure, especially in oncology doses. -
Renal Function (eGFR)
Baseline; then annually
Routine PK is not altered by renal impairment, but eGFR <30 markedly increases hypocalcemia risk. In CKD patients, evaluate for CKD-MBD (iPTH, bone turnover markers) before initiating. -
Signs of Infection
At each visit
Trigger-based Serious infections (cellulitis, endocarditis) were more frequent in denosumab-treated patients in the FREEDOM trial. Educate patients to report fever, erythema, or skin warmth promptly. -
Thigh / Groin Pain
At each visit
Trigger-based Prodromal symptom of atypical femoral fracture. If reported, obtain imaging of bilateral femurs. Consider interruption if fracture line identified.
Contraindications & Cautions
Absolute Contraindications
- Hypocalcemia: Pre-existing hypocalcemia must be corrected before initiating denosumab. Fatal cases of uncorrected hypocalcemia have been reported (FDA PI).
- Pregnancy (Prolia): Denosumab is formally contraindicated in pregnant women for Prolia indications. Animal studies at pharmacologically active doses demonstrated fetal loss, absent lymph nodes, and skeletal abnormalities.
- Known systemic hypersensitivity: Prior anaphylaxis, angioedema, or urticaria to denosumab or any excipient.
Relative Contraindications (Specialist Input Recommended)
- Advanced CKD (eGFR <30) without CKD-MBD evaluation: These patients face substantially elevated hypocalcemia risk. Treatment should only proceed under specialist supervision after thorough metabolic workup and with intensive calcium monitoring.
- Active or planned invasive dental procedures: ONJ risk is highest in patients with concurrent dental surgery. A comprehensive dental evaluation and completion of necessary procedures is recommended before initiating denosumab.
- Active serious infection: The decision to treat should weigh the risk of immunosuppressive effects of RANKL inhibition against the benefit of fracture or SRE prevention.
Use with Caution
- Concurrent immunosuppressive therapy: Additive infection risk; closer monitoring warranted.
- Patients with pre-existing dermatologic conditions: Eczema, dermatitis, and rash occurred at higher rates in the FREEDOM trial.
- Prolonged treatment (>5–10 years): Long-term bone turnover suppression may contribute to ONJ and atypical fractures. Reassess benefit-risk periodically.
- Latex-sensitive individuals: The gray needle cap of the Prolia prefilled syringe contains dry natural rubber (a latex derivative).
FDA Boxed Warning
Severe Hypocalcemia in Patients with Advanced Kidney Disease
Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m2), including those on dialysis, face a markedly elevated risk of severe hypocalcemia following denosumab administration. Fatal cases have been reported. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) further amplifies this risk. Prior to initiating Prolia in these patients, evaluate for CKD-MBD with iPTH, serum calcium, 25(OH)D, and 1,25(OH)2D. Treatment should be supervised by a healthcare provider with expertise in CKD-MBD management. This boxed warning was added in January 2024.
Patient Counselling
Purpose of Therapy
Denosumab is given to strengthen bones and reduce the risk of fractures. For patients with osteoporosis, it works by blocking a protein (RANKL) that causes bone breakdown. For patients with cancer that has spread to the bones, it helps prevent bone complications such as fractures, spinal cord compression, and the need for radiation or surgery to bone. The injection is given under the skin by a healthcare provider, typically every 6 months for osteoporosis or every 4 weeks for cancer-related bone conditions.
How to Take
Each injection is administered by a healthcare provider in a clinic setting. Patients must take daily calcium (1000 mg) and vitamin D (at least 400 IU) supplements throughout treatment. It is essential to keep all scheduled appointments and not miss doses. If a dose is delayed, it should be given as soon as possible, with subsequent doses rescheduled from that date. Patients should never stop denosumab without discussing a transition plan with their prescriber, as abrupt discontinuation can lead to rapid bone loss and an increased risk of spinal fractures.
Low Calcium (Hypocalcemia)
Tell patient
Take calcium and vitamin D supplements every day as directed. Low calcium is the most important side effect to watch for, especially in the first few weeks after the injection.
Call prescriber
Muscle spasms or twitching, tingling or numbness in fingers, toes, or around the mouth, or feeling confused or unusually tired.
Dental Health & Jaw Problems
Tell patient
Inform all dentists and oral surgeons that you are receiving denosumab before any dental procedure. Maintain good oral hygiene by brushing, flossing, and having regular dental check-ups. A dental examination should be completed before starting treatment.
Call prescriber
Jaw pain, numbness or heaviness in the jaw, loose teeth, exposed bone or gum ulcers, or slow healing after any dental procedure.
Thigh or Hip Pain
Tell patient
In rare cases, unusual fractures of the thigh bone can occur. These sometimes begin as a dull aching pain in the thigh, hip, or groin area weeks before the bone breaks.
Call prescriber
Any new or worsening pain in the thigh, hip, or groin, especially if it comes on gradually and persists.
Infection Risk
Tell patient
Serious infections, including skin infections (cellulitis), can occur more frequently with denosumab. Practice good wound care and avoid contact with sick individuals where possible.
Call prescriber
Fever, chills, areas of red/warm/swollen skin, abdominal pain, burning on urination, or any signs of a skin infection.
Do Not Stop Treatment Without a Plan
Tell patient
Stopping denosumab without switching to another bone-strengthening medicine can lead to rapid bone loss and multiple spine fractures. Always discuss any planned discontinuation with your doctor, who will arrange a transition to another medication.
Call prescriber
If you have missed a scheduled injection by more than a few weeks, or if you are considering stopping treatment for any reason.
Pregnancy & Contraception
Tell patient
Denosumab can harm an unborn baby. Women who could become pregnant must use effective contraception during treatment and for at least 5 months after the last dose. A pregnancy test is required before each injection.
Call prescriber
Immediately if you think you may be pregnant or are planning to become pregnant.
Sources
Regulatory (PI / SmPC)
- Prolia (denosumab) prescribing information. Amgen Inc. Revised April 2025. FDA Label Primary source for all Prolia-related dosing, indications, adverse reactions, PK data, and the boxed warning for severe hypocalcemia in advanced CKD.
- Xgeva (denosumab) prescribing information. Amgen Inc. Revised May 2025. FDA Label Primary source for oncology indications including bone metastases, GCTB, and hypercalcemia of malignancy; includes Xgeva-specific PK and safety data.
- FDA Drug Safety Communication: Prolia — risk of severe hypocalcemia in patients with advanced kidney disease. January 2024. FDA.gov Documents the addition of the boxed warning, including reports of fatal hypocalcemia in CKD patients.
Key Clinical Trials
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. DOI: 10.1056/NEJMoa0809493 The pivotal FREEDOM trial (N = 7868) demonstrating 68% reduction in vertebral fractures, 40% in hip fractures, and 20% in nonvertebral fractures vs placebo over 3 years.
- Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9 Long-term safety and efficacy data showing continued BMD gains and low fracture rates over 10 years of continuous treatment.
- Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822. DOI: 10.1016/S0140-6736(10)62344-6 Phase 3 trial (N = 1901) showing Xgeva superiority over zoledronic acid in delaying first SRE in men with CRPC bone metastases.
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139. DOI: 10.1200/JCO.2010.29.7101 Phase 3 trial in breast cancer bone metastases demonstrating superior delay of first SRE with denosumab versus zoledronic acid.
Guidelines
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL Positions denosumab as initial or second-line therapy for postmenopausal osteoporosis and addresses transition strategies upon discontinuation.
- Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-1537. DOI: 10.1002/art.40137 Recommends denosumab as an option for GIO patients who cannot tolerate bisphosphonates or have contraindications to oral therapy.
Mechanistic / Basic Science
- Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-419. DOI: 10.1038/nrd3705 Comprehensive review of RANKL biology and the translational development of denosumab from discovery through clinical application.
Pharmacokinetics / Special Populations
- Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793-807. DOI: 10.2165/11594240-000000000-00000 Population PK analysis establishing bioavailability of 61%, nonlinear PK at low doses, and the influence of body weight on clearance and distribution.
- Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012;51(4):247-260. DOI: 10.2165/11598090-000000000-00000 PK characterization in oncology patients showing bioavailability of 61%, steady state by 6 months, and body weight-proportional clearance.
- Watts NB, Brown JP, Papapoulos S, et al. Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to denosumab during the FREEDOM extension. J Bone Miner Res. 2017;32(7):1481-1490. DOI: 10.1002/jbmr.3119 Detailed safety analysis comparing AE rates in crossover and long-term denosumab groups, including top adverse reactions and infection rates.